Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia.

García Martín A, Varsavsky M, Cortés Berdonces M, Ávila Rubio V, Alhambra Expósito MR, Novo Rodríguez C, Rozas Moreno P, Romero Muñoz M, Jódar Gimeno E, Rodríguez Ortega P, Muñoz Torres M.

Endocrinol Diabetes Nutr. 2019 Sep 6. pii: S2530-0164(19)30171-5. doi: 10.1016/j.endinu.2019.06.004. [Epub ahead of print] English, Spanish.

PMID:
31501071
2.

Is vitamin-D supplementation not useful in patients at risk of fractures and falls?

Aguilar Del Rey J, Jódar Gimeno E, Brañas Baztán F, Gómez Alonso C, González Lama Y, Malouf Sierra J, Borrego RS, Segura de la Morena J, Suárez Pérez JA, Valdés Y Llorca C.

Gynecol Endocrinol. 2020 Feb;36(2):93-95. doi: 10.1080/09513590.2019.1650346. Epub 2019 Aug 7.

PMID:
31389272
3.

IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.

Miller E, Doshi A, Grøn R, Jódar E, Őrsy P, Ranthe MF, Sugimoto D, Tentolouris N, Viljoen A, Billings LK.

Diabetes Obes Metab. 2019 Dec;21(12):2643-2650. doi: 10.1111/dom.13851. Epub 2019 Aug 28.

4.

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Leiter LA, Bain SC, Hramiak I, Jódar E, Madsbad S, Gondolf T, Hansen T, Holst I, Lingvay I.

Cardiovasc Diabetol. 2019 Jun 6;18(1):73. doi: 10.1186/s12933-019-0871-8.

5.

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.

Billings LK, Mocarski M, Basse A, Hunt B, Valentine WJ, Jodar E.

Clinicoecon Outcomes Res. 2019 Mar 21;11:271-282. doi: 10.2147/CEOR.S194719. eCollection 2019.

6.

Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide.

Fonseca VA, Capehorn MS, Garg SK, Jódar Gimeno E, Hansen OH, Holst AG, Nayak G, Seufert J.

J Clin Endocrinol Metab. 2019 Apr 2. pii: jc.2018-02685. doi: 10.1210/jc.2018-02685. [Epub ahead of print]

PMID:
30938762
7.

Document on a comprehensive approach to type 2 diabetes mellitus.

Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, de la Torre Casares ML, Rozas-Moreno P, Fernández-García JC, Marco Martínez A, Escalada-San Martín J, Gargallo-Fernández M, Botana-López M, López-Fernández J, González-Clemente JM, Jódar-Gimeno E, Mezquita-Raya P; en representación del Grupo de trabajo de Diabetes-SEEN.

Endocrinol Diabetes Nutr. 2019 Aug - Sep;66(7):443-458. doi: 10.1016/j.endinu.2018.10.010. Epub 2019 Feb 28. English, Spanish.

PMID:
30827909
8.

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.

Vilsbøll T, Blevins TC, Jodar E, Poulter N, Tentolouris N, Ross Agner BF, Lehmann L, Leiter LA.

Diabetes Obes Metab. 2019 Jun;21(6):1506-1512. doi: 10.1111/dom.13675. Epub 2019 Apr 8.

9.

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, Mehta R, Woo V, Lingvay I.

Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4. Review.

PMID:
30615985
10.

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.

Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Ann Intern Med. 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. No abstract available.

PMID:
30508430
11.

Position statement for the management of comorbidities in psoriasis.

Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, Quintero J, Rivera R.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2058-2073. doi: 10.1111/jdv.15177. Epub 2018 Aug 14. Review.

PMID:
29992631
12.

Consensus document on osteoporosis in males.

Varsavsky M, Romero Muñoz M, Ávila Rubio V, Becerra A, García Martín A, Martínez Díaz-Guerra G, Rozas Moreno P, Jódar Gimeno E, Muñoz Torres M.

Endocrinol Diabetes Nutr. 2018 Mar;65 Suppl 1:9-16. doi: 10.1016/j.endinu.2017.12.005. Epub 2018 Mar 9. English, Spanish.

PMID:
29530627
13.

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.

Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E.

Diabetes Care. 2018 May;41(5):1009-1016. doi: 10.2337/dc17-1114. Epub 2018 Feb 26.

PMID:
29483185
14.

Spanish consensus on treat to target for osteoporosis.

Nogués X, Nolla JM, Casado E, Jódar E, Muñoz-Torres M, Quesada-Gómez JM, Canals L, Balcells M, Lizán L.

Osteoporos Int. 2018 Feb;29(2):489-499. doi: 10.1007/s00198-017-4310-y. Epub 2017 Nov 24.

15.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A.

Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.

PMID:
28755782
16.

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.

Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E.

Diabetes Obes Metab. 2018 Jan;20(1):200-205. doi: 10.1111/dom.13043. Epub 2017 Jul 31.

17.

Recommended vitamin D levels in the general population.

Varsavsky M, Rozas Moreno P, Becerra Fernández A, Luque Fernández I, Quesada Gómez JM, Ávila Rubio V, García Martín A, Cortés Berdonces M, Naf Cortés S, Romero Muñoz M, Reyes García R, Jódar Gimeno E, Muñoz Torres M; en representación del Grupo de Trabajo de Osteoporosis y Metabolismo Mineral de la Sociedad Española de Endocrinología y Nutrición.

Endocrinol Diabetes Nutr. 2017 Mar;64 Suppl 1:7-14. doi: 10.1016/j.endinu.2016.11.002. Epub 2017 Feb 15. English, Spanish.

PMID:
28440763
18.

Recommendations on the effect of antidiabetic drugs in bone.

Rozas-Moreno P, Reyes-García R, Jódar-Gimeno E, Varsavsky M, Luque-Fernández I, Cortés-Berdonces M, Muñoz-Torres M; en representación del Grupo de Trabajo de Osteoporosis y Metabolismo Mineral de la Sociedad Española de Endocrinología y Nutrición.

Endocrinol Diabetes Nutr. 2017 Mar;64 Suppl 1:1-6. doi: 10.1016/j.endinu.2016.11.001. Epub 2017 Feb 16. English, Spanish.

PMID:
28440761
19.

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).

Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z.

Diabetes Obes Metab. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. Epub 2017 Apr 10.

PMID:
28294499
20.

[ZODIAC: Consensus on herpes zoster prevention in persons with diabetes mellitus].

Redondo Margüello E, Mauricio D, Mediavilla Bravo JJ, Soto González A, Delgado Álvarez E, Ampudia-Blasco FJ, Jódar Gimeno E.

Semergen. 2016 Nov;42 Suppl 3:1-19. doi: 10.1016/S1138-3593(16)30246-5. Spanish. No abstract available.

PMID:
27916198

Supplemental Content

Loading ...
Support Center